Immunotherapy Biomarkers

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Marta Casarrubios, Mariano Provencio, Ernest Nadal, Amelia Insa, María del Rosario García-Campelo, Martín Lázaro-Quintela, Manuel Dómine, Margarita Majem, Delvys Rodriguez-Abreu, Alex Martinez-Marti, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé, Nuria Viñolas, Isidoro Barneto Aranda, Bartomeu Massuti, Belén Sierra-Rodero, Cristina Martinez-Toledo, Ismael Fernández-Miranda, Roberto Serna-Blanco, Atocha Romero, Virginia Calvo, Alberto Cruz-Bermúdez

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005320; DOI: 10.1136/jitc-2022-005320
Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
Sonia Simonetti, Michele Iuliani, Marco Stellato, Silvia Cavaliere, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Francesco Pantano

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005136; DOI: 10.1136/jitc-2022-005136
Label-free metabolic imaging for sensitive and robust monitoring of anti-CD47 immunotherapy response in triple-negative breast cancer
Minfeng Yang, Arpan Mahanty, Chunjing Jin, Alex Ngai Nick Wong, Jung Sun Yoo

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005199; DOI: 10.1136/jitc-2022-005199
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study
Ji Hyun Lee, Sujin Hyung, Jeeyun Lee, Sang-Hee Choi

Journal for ImmunoTherapy of Cancer Aug 2022, 10 (8) e005226; DOI: 10.1136/jitc-2022-005226
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer
Myrto K Moutafi, Magdalena Molero, Sandra Martinez Morilla, Javier Baena, Ioannis A Vathiotis, Niki Gavrielatou, Laura Castro-Labrador, Gorka Ruiz de Garibay, Vera Adradas, Daniel Orive, Karmele Valencia, Alfonso Calvo, Luis M Montuenga, S Ponce Aix, Kurt A Schalper, Roy S Herbst, Luis Paz-Ares, David L Rimm, Jon Zugazagoitia

Journal for ImmunoTherapy of Cancer Aug 2022, 10 (8) e004757; DOI: 10.1136/jitc-2022-004757
Single-cell analysis reveals clonally expanded tumor-associated CD57⁺ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
Michael Fehlings, Leesun Kim, Xiangnan Guan, Kobe Yuen, Alireza Tafazzol, Shomyseh Sanjabi, Oliver A Zill, Deepali Rishipathak, Andrew Wallace, Alessandra Nardin, Siming Ma, Ana Milojkovic, Evan W Newell, Sanjeev Mariathasan, Mahesh Yadav

Journal for ImmunoTherapy of Cancer Aug 2022, 10 (8) e004759; DOI: 10.1136/jitc-2022-004759
Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
Shiro Takamatsu, Junzo Hamanishi, J B Brown, Ken Yamaguchi, Koji Yamanoi, Kosuke Murakami, Osamu Gotoh, Seiichi Mori, Masaki Mandai, Noriomi Matsumura

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e004831; DOI: 10.1136/jitc-2022-004831
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
Rita C. Acúrcio, Sabina Pozzi, Barbara Carreira, Marta Pojo, Nuria Gómez-Cebrián, Sandra Casimiro, Adelaide Fernandes, Andreia Barateiro, Vitor Farricha, Joaquim Brito, Ana Paula Leandro, Jorge A R Salvador, Luís Graça, Leonor Puchades-Carrasco, Luís Costa, Ronit Satchi-Fainaro, Rita C. Guedes, Helena F. Florindo

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e004695; DOI: 10.1136/jitc-2022-004695
Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities
Jian Lin, Yuting Dai, Chen Sang, Guohe Song, Bin Xiang, Mao Zhang, Liangqing Dong, Xiaoli Xia, Jiaqiang Ma, Xia Shen, Shuyi Ji, Shu Zhang, Mingjie Wang, Hai Fang, Xiaoming Zhang, Xiangdong Wang, Bing Zhang, Jian Zhou, Jia Fan, Hu Zhou, Daming Gao, Qiang Gao

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e004892; DOI: 10.1136/jitc-2022-004892
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
Jennifer Wilkinson Carlisle, Caroline S Jansen, Maria Andrea Cardenas, Ewelina Sobierajska, Adriana Moon Reyes, Rachel Greenwald, Luke Del Balzo, Nataliya Prokhnevska, Omer Kucuk, Bradley C Carthon, Patrick Connor Mullane, Adeboye Osunkoya, Deborah Baumgarten, Fares Hosseinzadeh, Scott Wilkinson, Ross Lake, Adam G Sowalsky, Yuan Liu, Viraj A Master, Mehmet A Bilen, Haydn Kissick

Journal for ImmunoTherapy of Cancer Jul 2022, 10 (7) e004803; DOI: 10.1136/jitc-2022-004803

Main menu

Immunotherapy Biomarkers

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy Biomarkers

Pages